Novo says results held across menopausal stages among 1,900 women, from 23.1% to 26.7%, against about 2% on placebo. The piece also pitches obesity ETFs.
Recap by typeshit. Full story at The Globe and Mail.
The REDEFINE 1 data covered 2,309 women, with placebo at 3%. In the REDEFINE 4 head-to-head, tirzepatide matched or slightly beat it.
Superpower says the drug carries radiation straight to cancer cells and cites a phase 3 trial showing a 79% lower risk of progression or death. A 14-part thread.
Australian experts note about half a million people there use GLP-1 drugs for diabetes alone, and lay out what new users should keep in mind about nutrition.
A herpetology-themed clip from PBS points to reptiles as part of the story behind today's GLP-1 medications. Short and light, but a fun bit of history.
MUSC Health suggests the familiar ABCs of heart health may change, with GLP-1 medications now part of cardiovascular prevention for some patients.
Led by Alabama's Steve Marshall, the AGs call the supply chain a security risk and say an FDA import list could be used to launder knock-off semaglutide.
Loading…